1. Wun, T, White, RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009; 22: 9–23. 2009/03/17. DOI: 10.1016/j.beha.2008.12.001
Google Scholar | Crossref | Medline | ISI2. Mege, D, Panicot-Dubois, L, Dubois, C. Mechanisms of cancer-associated thrombosis. HemaSphere 2019; 3: 19–21.
Google Scholar | Crossref3. Gordon, SG, Franks, JJ, Lewis, B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127–137. 1975/02/01. DOI: 10.1016/0049-3848(75)90018-3
Google Scholar | Crossref | Medline4. Gordon, SG, Mielicki, WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8: 73–86. 1997/03/01.
Google Scholar | Crossref | Medline5. Alessio, MG, Falanga, A, Consonni, R, et al. Cancer procoagulant in acute lymphoblastic leukemia. Eur J Haematol 1990; 45: 78–81. 1990/08/01. DOI: 10.1111/j.1600-0609.1990.tb00421.x
Google Scholar | Crossref | Medline6. Zhang, N, Lou, W, Ji, F, et al. Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J Cancer Res Clin Oncol 2016; 142: 1807–1816. 2016/02/26. DOI: 10.1007/s00432-016-2131-6
Google Scholar | Crossref | Medline7. Bobek, V, Kovarík, J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58: 213–219. 2004/06/09. DOI: 10.1016/j.biopha.2003.11.007
Google Scholar | Crossref | Medline | ISI8. Carrier, M, Abou-Nassar, K, Mallick, R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711–719. 2018/12/05. DOI: 10.1056/NEJMoa1814468
Google Scholar | Crossref | Medline9. Raskob, GE, van Es, N, Verhamme, P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–624. 2017/12/13. DOI: 10.1056/NEJMoa1711948
Google Scholar | Crossref | Medline10. Asanuma, K, Wakabayashi, H, Hayashi, T, et al. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004; 67: 166–173. 2004/11/13. DOI: 10.1159/000081004
Google Scholar | Crossref | Medline11. Ogawa, M, Jing, H, Kitts, DD, et al. In vitro anti-cancer activities in caco-2 and HCT-116 cells of recombinant cystatin C prepared by a pichia expression system. J Med Food 2003; 6: 317–322. 2004/02/24. DOI: 10.1089/109662003772519868
Google Scholar | Crossref | Medline12. Brüning, A, Friese, K, Burges, A, et al. Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res 2010; 12: R45. 2010/07/03. DOI: 10.1186/bcr2602
Google Scholar | Crossref | Medline13. Gills, JJ, Lopiccolo, J, Tsurutani, J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13: 5183–5194. 2007/09/06. DOI: 10.1158/1078-0432.ccr-07-0161
Google Scholar | Crossref | Medline | ISI14. Ariga, T, Tsuj, K, Seki, T, et al. Antithrombotic and antineoplastic effects of phyto-organosulfur compounds. Biofactors 2000; 13: 251–255. 2001/03/10. DOI: 10.1002/biof.5520130138
Google Scholar | Crossref | Medline15. Manjappa, B, Gangaraju, S, Girish, KS, et al. Momordica charantia seed extract exhibits strong anticoagulant effect by specifically interfering in intrinsic pathway of blood coagulation and dissolves fibrin clot. Blood Coagul Fibrinolysis 2015; 26: 191–199. 2014/09/06. DOI: 10.1097/mbc.0000000000000191
Google Scholar | Crossref | Medline16. Min, SK, Kwon, OC, Lee, S, et al. An antithrombotic fucoidan, unlike heparin, does not prolong bleeding time in a murine arterial thrombosis model: a comparative study of undaria pinnatifida sporophylls and fucus vesiculosus. Phytother Res 2012; 26: 752–757. 2011/11/16. DOI: 10.1002/ptr.3628
Google Scholar | Crossref | Medline17. Wang, H, Khor, TO, Shu, L, et al. Plants vs. Cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem 2012; 12: 1281–1305. 2012/05/16. DOI: 10.2174/187152012803833026
Google Scholar | Crossref | Medline18. Caine, GJ, Stonelake, PS, Lip, GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465–473. 2002/10/31. DOI: 10.1038/sj.neo.7900263
Google Scholar | Crossref | Medline | ISI19. Falanga, A, Consonni, R, Marchetti, M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92: 143–151. 1998/06/25.
Google Scholar | Crossref | Medline